David Hollander - 18 Nov 2024 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
RVNC
Transactions as of
18 Nov 2024
Transactions value $
-$16,296
Form type
4
Filing time
19 Nov 2024, 16:31:35 UTC
Previous filing
03 Jul 2024
Next filing
06 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale -$16,296 -3,908 -3.6% $4.17 104,945 18 Nov 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units granted on October 17, 2022 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.